Integer Holdings Corporation reports news as a medical device contract development and manufacturing organization serving cardio and vascular, neuromodulation, and cardiac rhythm management markets. Company updates commonly cover sales trends, organic growth, product-line performance, adjusted earnings measures, debt and leverage, and outlook commentary tied to customer programs and new product activity.
Integer news also includes governance and capital-allocation developments, including board composition, shareholder engagement, share repurchase authorization, investor conference participation, and broader strategy updates. The company’s public identity includes the Greatbatch Medical and Lake Region Medical brands and engineering and manufacturing work for medical device customers.
Integer Holdings Corporation (NYSE:ITGR) will announce its second quarter 2021 financial results on July 29, 2021, at 7 a.m. CT. A conference call will follow at 8 a.m. CT to discuss the results and other relevant information. Investors can participate through a domestic or international dial-in and access the webcast online. The company, a leading medical device manufacturer, aims to provide innovative technologies in various medical fields. Further information and updates can be found on their investor relations website.
Integer Holdings Corporation (NYSE:ITGR) reported its Q1 2021 results, with sales of $290 million, a 12% decline from the previous year. GAAP net income fell 31% to $22 million. Despite the pandemic's impact, sales and profits showed sequential improvement compared to Q4 2020. Integer is increasing its 2021 outlook, projecting 10%-12% sales growth, along with $90 million to $110 million in free cash flow. The company's total debt decreased by $25 million to $664 million, reflecting ongoing recovery and strategic execution.
Integer Holdings Corporation (NYSE:ITGR) announces its first quarter 2021 financial results release set for April 29, 2021, at 8 a.m. ET. The management will discuss these results in a conference call at 9 a.m. ET the same day. Investors can access the call via domestic and international dial-in numbers or through a webcast. Integer is a leading medical device outsource manufacturer, focusing on various markets including cardiac and orthopedics, and will also provide updates on additional forward-looking information during the call.
Integer Holdings Corporation (NYSE:ITGR) reported strong fourth quarter results with sales of $269 million, slightly above guidance but a 17% decline year-over-year. GAAP net income rose 40% to $15 million, while adjusted net income fell 43% to $23 million. The company reduced net total debt by $123 million in 2020, ending the year with $689 million in debt. For 2021, Integer projected sales growth of 8% to 12%, with first quarter sales expected to be sequentially better than Q4 2020. The company's operational excellence strategy aims for a return to profitable growth.
Integer Holdings Corporation has elected three new directors to its Board: Sheila Antrum, Cheryl Capps, and Alvin (Tyrone) Jeffers, enhancing its manufacturing and healthcare expertise. Antrum brings over 40 years in medical operations, currently serving as COO at UCSF Health. Capps, with 35 years in supply chain management, is the SVP at Corning Inc. Jeffers, with 24 years in manufacturing, is VP of Global Manufacturing at SPX FLOW. Integer aims to leverage their diverse perspectives to drive growth and execute strategic initiatives.
Integer Holdings Corporation (NYSE:ITGR) is set to announce its financial and operational results for Q4 and full-year 2020 on February 18, 2021, at 8 a.m. ET. A conference call will follow at 9 a.m. ET, where management will discuss the results and other material information. Interested parties can participate via a domestic dial-in number or an international number. A replay of the call will be available for seven days post-event, and the call will also be accessible on the company's Investor Relations website.
Integer Holdings Corporation (NYSE: ITGR) has announced a significant expansion at its Alden, NY facility to increase production capacity for Xcellion® Lithium Ion rechargeable batteries. The expansion, which began in December 2020, aims to enhance battery production for applications in neuromodulation and cochlear devices. The project includes new manufacturing equipment and facility upgrades, expected to complete in 2021. This strategic investment is designed to meet the growing demands of Integer's cardiac and neuromodulation customers.
Integer Holdings Corporation (NYSE:ITGR) reported its third-quarter results for 2020, highlighting a sales decline of 22% to $236 million, with GAAP income down 1% to $30 million. Non-GAAP adjusted income fell 58% to $17 million, while adjusted EBITDA dropped 47% to $37 million. The company expects fourth-quarter sales to improve by $20-$35 million and projects a 200-300 basis point increase in adjusted operating income margin. Integer received a $28 million patent litigation judgment, aiding its debt reduction efforts, with net total debt decreasing to $747 million.
Integer Holdings Corporation (NYSE: ITGR) has secured approximately $28 million from a Federal Court ruling in its favor against AVX Corporation for patent infringement. This outcome allows Integer to reduce its net debt by about 4%. The company emphasizes its commitment to protecting intellectual property, which supports its goal of enhancing patient lives through innovative medical technologies. Integer is a leading manufacturer in the medical device outsourcing space, catering to several critical healthcare markets.
Integer Holdings Corporation (NYSE:ITGR) is set to release its third quarter 2020 financial and operational results on October 29, 2020, at 8 a.m. ET. Following the results announcement, a management webcast will be held at 9 a.m. ET to discuss the outcomes and additional forward-looking information. Investors can join the conference call using specific dial-in numbers provided. Integer, a leading medical device manufacturer, specializes in cardiac, neuromodulation, vascular, and orthopedics markets, offering innovative medical technologies.